Adar1 Capital Management, LLC Kymera Therapeutics, Inc. Transaction History

Adar1 Capital Management, LLC

  • $1.06 Trillion
  • Q3 2025

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$21.05 - $48.6 $70,854 - $163,587
3,366 Added 33.66%
13,366 $583 Million
Q4 2024

Feb 13, 2025
SELL
$39.06 - $51.84 $72,495 - $96,215
-1,856 Reduced 15.65%
10,000 $402 Million
Q3 2024

Nov 14, 2024
SELL
$30.16 - $52.4 $1.17 Million - $2.03 Million
-38,770 Reduced 76.58%
11,856 $561 Million
Q2 2024

Aug 13, 2024
BUY
$29.85 - $39.42 $1.03 Million - $1.36 Million
34,626 Added 216.41%
50,626 $1.51 Billion
Q1 2024

May 15, 2024
BUY
$22.9 - $43.57 $366,400 - $697,120
16,000 New
16,000 $643 Million

Others Institutions Holding KYMR

# of Institutions
223
Shares Held
74M
Call Options Held
144K
Put Options Held
58.1K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $3.55B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email